Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRDF
stocks logo

CRDF

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
106.25K
-29.64%
-0.190
-9.52%
80.00K
-26.61%
-0.180
-10%
80.00K
-33.88%
-0.182
-13.49%
Estimates Revision
The market is revising Upward the revenue expectations for Cardiff Oncology, Inc. (CRDF) for FY2025, with the revenue forecasts being adjusted by 6.73% over the past three months. During the same period, the stock price has changed by -0.46%.
Revenue Estimates for FY2025
Revise Upward
up Image
+6.73%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.78%
In Past 3 Month
Stock Price
Go Down
down Image
-0.46%
In Past 3 Month
Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.160
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 2.160
sliders
Low
10.00
Averages
10.00
High
10.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$18 -> $10
2025-08-06
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$18 -> $10
2025-08-06
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cardiff Oncology to $10 from $18 and keeps a Buy rating on the shares following the Q2 report. The firm reduced its probability of approval for onvansertib to 25% from 40%, seeing a higher risk profile following the most recent data.
Ladenburg
Kevin Degeeter
Buy
initiated
$19
2025-07-08
Reason
Ladenburg
Kevin Degeeter
Price Target
$19
2025-07-08
initiated
Buy
Reason
Ladenburg analyst Kevin Degeeter initiated coverage of Cardiff Oncology with a Buy rating and $19 price target. The firm, which sees potential for onvansertib to become a new treatment option for first-line KRAS and NRAS mutated colorectal cancer, expects a planned update on July 29 to clarify the tolerability profile and potentially enable selection of an onvansertib dose for Phase 3 development.
Jefferies
Hold
initiated
$3.50
2025-06-24
Reason
Jefferies
Price Target
$3.50
2025-06-24
initiated
Hold
Reason
Jefferies initiated coverage of Cardiff Oncology with a Hold rating and $3.50 price target. The company's onvansertib has shown promising early data in 1L RAS mutations metastatic colorectal cancer, but the data are early and the drug's mechanism of action is risky with prior failed studies, the analyst tells investors in a research note. The firm believes catalysts for rest of year may not provide adequate efficacy insight. It plans to reassess the Hold rating post the July 29 data update.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$18
2025-06-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$18
2025-06-19
maintain
Buy
Reason
H.C. Wainwright
Robert Burns
Buy
upgrade
$17 -> $18
2025-05-09
Reason
H.C. Wainwright
Robert Burns
Price Target
$17 -> $18
2025-05-09
upgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Cardiff Oncology to $18 from $17 and keeps a Buy rating on the shares following the Q1 report.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$13 → $17
2025-02-28
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$13 → $17
2025-02-28
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cardiff Oncology Inc (CRDF.O) is -2.85, compared to its 5-year average forward P/E of -4.74. For a more detailed relative valuation and DCF analysis to assess Cardiff Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.74
Current PE
-2.85
Overvalued PE
0.58
Undervalued PE
-10.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
695.01
Current PS
0.00
Overvalued PS
1279.73
Undervalued PS
110.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 901.42% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 901.42% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRDF News & Events

Events Timeline

(ET)
2025-11-06
18:02:27
Cardiff Oncology increases FY25 revenue forecast to $76M-$78M, up from $72M-$76M
select
2025-11-06
17:59:01
Cardiff Oncology Announces Q3 Earnings Per Share of 17 Cents, Below Consensus Estimate of 21 Cents
select
2025-07-29 (ET)
2025-07-29
16:59:53
Cardiff Oncology announces data from CRDF-004 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-28NASDAQ.COM
Healthcare Rally: Pulmonx, UHS, and X4 Experience After-Hours Gains Following Strategic Announcements

  • Pulmonx Corp. Performance: Pulmonx Corp. saw a significant increase of 33.33% to $2.08 after announcing preliminary Q3 2025 revenue of approximately $21.5 million and leadership changes, including the reappointment of Glen French as President and CEO.

  • Q32 Bio Inc. Gains: Q32 Bio Inc. experienced a 12.5% rise to $3.15 in after-hours trading, although no specific news was reported to explain this increase.

  • Universal Health Services Update: Universal Health Services Inc. climbed 7.41% to $229.90 following its Q3 results and a revised full-year forecast, along with a $1.5 billion increase in its stock repurchase program.

  • X4 Pharmaceuticals Offering: X4 Pharmaceuticals Inc. gained 5.35% to $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses, increasing total shares outstanding to 79.2 million.

[object Object]
Preview
6.0
08-06Benzinga
AMD To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday

  • Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets and ratings for several companies, with Oppenheimer raising Frontdoor's target to $63, while UBS cut Gartner's target to $270.

  • Stock Performance Updates: Other notable changes include Needham increasing Toast's target to $60, and HC Wainwright reducing Cardiff Oncology's target to $10, reflecting mixed sentiments across different stocks.

[object Object]
Preview
5.0
08-01NASDAQ.COM
Friday 8/1 Insider Buying Report: CRDF, MBIN

  • Insider Purchases: Gary W. Pace bought 290,000 shares of Cardiff Oncology (CRDF) for $710,500, while CEO Michael R. Dury purchased $504,936 worth of Merchants Bancorp (MBIN), indicating confidence in both companies despite their varying stock performances.

  • Market Performance: Cardiff Oncology's stock rose by 14.6% on Friday, while Merchants Bancorp saw a slight increase of 0.3%, with shares available at a lower price than Dury's recent purchase.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cardiff Oncology Inc (CRDF) stock price today?

The current price of CRDF is 2.16 USD — it has increased 1.41 % in the last trading day.

arrow icon

What is Cardiff Oncology Inc (CRDF)'s business?

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

arrow icon

What is the price predicton of CRDF Stock?

Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cardiff Oncology Inc (CRDF)'s revenue for the last quarter?

Cardiff Oncology Inc revenue for the last quarter amounts to 120.00K USD, decreased -27.27 % YoY.

arrow icon

What is Cardiff Oncology Inc (CRDF)'s earnings per share (EPS) for the last quarter?

Cardiff Oncology Inc. EPS for the last quarter amounts to -0.17 USD, decreased -32.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cardiff Oncology Inc (CRDF)'s fundamentals?

The market is revising Upward the revenue expectations for Cardiff Oncology, Inc. (CRDF) for FY2025, with the revenue forecasts being adjusted by 6.73% over the past three months. During the same period, the stock price has changed by -0.46%.
arrow icon

How many employees does Cardiff Oncology Inc (CRDF). have?

Cardiff Oncology Inc (CRDF) has 32 emplpoyees as of December 05 2025.

arrow icon

What is Cardiff Oncology Inc (CRDF) market cap?

Today CRDF has the market capitalization of 145.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free